MESOBLAST LTD (MESO) Form 6-K — Oct 15, 2026
Mesoblast reported a 44% year-over-year increase in Ryoncil net revenue to US$28 million for its first fiscal quarter ended September 30, up from US$19 million in the prior year period. Net operational cash spend improved 85% to US$2.3 million from US$14.9 million, and the company ended the quarter with US$99 million in cash. September saw the highest number of new Ryoncil patient starts per month as summer-recess-related seasonality in July and August faded. Management plans continued growth by increasing penetration across 54 onboarded sites.
Key figures
- Revenue
- 28000000
- Revenue Yoy
- 44%
- Cash Position
- 99000000
- Onboarded sites
- 54
- Cash spend improvement
- 85%
- Net operating cash spend
- US$2.3 million
- Prior year ryoncil revenue
- US$19 million
- Prior year net operating cash spend
- US$14.9 million
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.